Use this URL to cite or link to this record in EThOS: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.815315
Title: Biophysical and biochemical characterizations of parasitic and human PDEs as potential drug targets
Author: Dodina, Maria
ISNI:       0000 0004 9357 3907
Awarding Body: University of Kent
Current Institution: University of Kent
Date of Award: 2020
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Please try the link below.
Access from Institution:
Abstract:
Kinetoplastid parasites are a family of Trypanosomatids that cause a number of diseases worldwide; Leishmaniasis, Chagas disease and African Sleeping sickness are collectively termed as neglected parasitic diseases (NTDs). In the current study the main focus will be on 2 main infections: Leishmaniasis - caused by Leishmania species and African sleeping sickness - caused by T. brucei. There are 700,000 to 1 million cases of Leishmaniasis that are registered, with 26,000 to 65,000 deaths annually, whereas sleeping sickness causes 10,000 reported cases annually and Chagas disease is reported to have 6 to 7 million people being infected worldwide. The main countries that are at risk are 3rd world countries with tropical and sub-tropical regions where the health system is not well developed. Kinetoplastid organisms are characterized by having single flagellum and containing a particular organelle called kinetoplast. Leishmaniasis is a parasitic disease that is a widely distributed and causes endemic waves of outbreak in 100 countries in the regions of Asia, Africa, Latin America and even Southern Europe. More than 300 million people are at risk to develop this health condition. Leishmaniasis is a tropical health condition that mainly predominates in countries with poorly developed health system. Also, factors such as climate and environment can have a significant effect on disease transmission and occurrence. Infection is transmitted by female phlebotomine sandflies. There is a significant discussion on the treatment of Leishmaniasis and other tropical diseases that can be used in order to control its transmission as well as the development of new cases worldwide. Nowadays, there is an increased risk of infection as the modern world is more dynamic in terms of tourism and immigration, and global warming could also be a factor to the disease being more widespread and being able to be transmitted to other European countries (World Health Organization). Treatments for Leishmaniasis include use of pentavalent antimonial (meglumine antimoniate & sodium stibogluconate), paromomycin, sitamaquine, amphotericin B, miltesfosine and pentamidine drugs. However, there are certain drawbacks of current treatments, such as: drug's potency against infection, effectiveness on late stages, rising resistance and its cost. Historically, a Dihydroartemisinin (artesunate) derivative was the therapy recommended by WHO (World Health Organization) and is also often used to treat Plasmodium falciparum malaria in tropical and subtropical countries.
Supervisor: Brown, David Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.815315  DOI: Not available
Keywords: QH Natural history
Share: